Form 4: Vera Therapeutics Insider Sells Shares Under 10b5-1 Plan

Vera Therapeutics President and CEO, Marshall Fordyce, reported the sale of over 46,000 shares of Class A Common Stock through a pre-arranged 10b5-1 trading plan.

Summary

• Marshall Fordyce, President and CEO of Vera Therapeutics, Inc., reported transactions on July 7, 2026.
• These transactions involved the sale of Class A Common Stock.
• The sales were executed under a written trading plan adopted on January 9, 2026, which complies with Rule 10b5-1(c) requirements.
• A total of 46,000 shares were sold across multiple transactions at weighted-average prices ranging from $40.39 to $43.97.
• Following these sales, Fordyce beneficially owns 122,949 shares indirectly via a GRAT and 99,081 shares indirectly via a Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-arranged 10b5-1 plan, mitigating concerns about insider trading based on non-public information.

Negatives

• Insider selling activity can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established 10b5-1 plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives to diversify holdings or manage personal finances, and are generally viewed as less indicative of negative sentiment than unannounced sales.

Stakeholder Impact

• Shareholders may note the sale of shares by a key executive, though the 10b5-1 plan context suggests it's a pre-planned diversification rather than a signal of negative outlook.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Marshall Fordyce, Class A Common Stock